title: Reply by the authors to the comments of Mortimer Lorber, MD.
authors.affiliation: Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri 63104, USA.
authors.forename: Stephanie M
authors.initials: SM
authors.lastname: Knebel
authors.forename: Randy S
authors.initials: RS
authors.lastname: Sprague
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism*; D000242:Cyclic AMP / Q000378:metabolism*; D011464:Epoprostenol / Q000494:pharmacology*; D004912:Erythrocytes / Q000187:drug effects*; D005260:Female; D006801:Humans; D008297:Male; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology*; D014665:Vasodilator Agents / Q000494:pharmacology*
chemical_list: D010726:Phosphodiesterase Inhibitors; D014665:Vasodilator Agents; D000255:Adenosine Triphosphate; D011464:Epoprostenol; D000242:Cyclic AMP